Navigation Links
ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Date:1/25/2008

TORONTO, Jan. 25 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced it will hold a conference call to discuss its fourth quarter and year end 2007 results at 8:00 a.m. (Eastern Time) on Tuesday, January 29, 2008. The Company will report its results in a press release to be issued at 7:00 a.m. prior to the call.

DATE: Tuesday, January 29, 2008

TIME: 8:00 a.m., Eastern Standard Time

WEBCAST: A live audio webcast of the call will be available at http://www.ariusmabs.com. Webcast attendees are welcome to listen to the conference in real-time or on-demand at their convenience. The webcast will be archived for 365 days. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

TAPED REPLAY: 416-644-3414 or 1-800-731-6941 (Available until

February 5, 2008)

REFERENCE NUMBER: 21261080

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Forward-Looking Statements

Certain statements in this news release constitute
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
2. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
3. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
4. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
5. ARIUS to present at Chinese Global Financial Forum
6. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
7. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
8. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
9. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Stem Cell Technology Center, LLC ( ASCTC ) was reported ... research that might benefit ALS patients. Because of ASCTC's ... cell technologies and therapeutic applications, FRC listed ASCTC as one ... donors who wish not to support research that requires the ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... Despite a number of key issues such as land use ... uses, global use of biofuels is excepted to more than ... analysis released today by Hart,s Global Biofuels Center. Leading the ... biofuels use of more than 35%. Brazil will grow domestic ...
... , DURHAM, N.C., Sept. 29 Oxygen Biotherapeutics, ... a new presentation for investors by company chairman ... the company website. The link to the presentation ... the Investor Relations section of the website at ...
... ANN ARBOR, Mich.---University of Michigan physicists have created ... major step toward the goal of producing "designer ... Quantum dots---often called artificial atoms or nanoparticles---are ... computing, photovoltaic cells, light-emitting devices and other technologies. ...
Cached Biology Technology:Global Biofuels Growth to Double by 2015 2Global Biofuels Growth to Double by 2015 3Global Biofuels Growth to Double by 2015 4U-M physicists create first atomic-scale map of quantum dots 2
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
(Date:8/29/2014)... researcher from the University of Texas Medical Branch at Galveston ... monoclonal antibodies can completely protect monkeys against a lethal dose ... a time when the disease is severe. , Thomas Geisbert, ... Nature discussing advances in Ebola treatment research. The ... the most deadly of pathogens, with fatality rates of up ...
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
... our bones undergo remodeling every day of our lives, as ... form. In diseases such as osteoporosis, an imbalance in this ... at the Weizmann Institute of Science, which recently appeared in ... how the roving cells whose job is to digest bone ...
... lung cancer with "moderate accuracy" even in the early stages, ... could revolutionise the way cancer is detected and potentially save ... chemical colour sensor, which detects tiny changes in the unique ... , Metabolic changes in lung cancer cells cause changes ...
... report that freezing kidney tumors through percutaneous cryoablation shows ... surgery. Their early findings showing short-term success in ... in this month’s issue of Radiology. , The standard ... likelihood of a long-term cure. For some patients, ...
Cached Biology News:Ring-around-the-cell 2Cryoablation -- A new treatment option for some kidney tumor patients 2Cryoablation -- A new treatment option for some kidney tumor patients 3
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
CMRL Medium-1066 (1X) liquid...
... (PEBP) does not share significant homology ... PEBP is expressed in the central ... and stomach. One important role ... inhibitory activity against several serine proteases ...
karyopherin alpha2 (2G7)...
Biology Products: